Clinical Trial Update: Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing pembrolizumab to paclitaxel in Asian patients with advanced gastric or gastroesophageal junction adenocarcinoma after platinum and fluor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma | Phase 3 | Status: TERMINATED | Results posted: 2023-03-30